Iron addiction: a novel therapeutic target in ovarian cancer
Oncogene, 2017 - nature.com
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
Iron addiction: a novel therapeutic target in ovarian cancer
D Basuli, L Tesfay, Z Deng, B Paul… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
[引用][C] Iron addiction: a novel therapeutic target in ovarian cancer
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto… - Oncogene, 2017 - cir.nii.ac.jp
Iron addiction: a novel therapeutic target in ovarian cancer | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
Iron addiction: a novel therapeutic target in ovarian cancer
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto… - Oncogene, 2017 - go.gale.com
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
[HTML][HTML] Iron addiction: A novel therapeutic target in ovarian cancer
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto… - Oncogene, 2017 - ncbi.nlm.nih.gov
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
Iron addiction: a novel therapeutic target in ovarian cancer.
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto… - 2017 - mouseion.jax.org
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
Iron addiction: a novel therapeutic target in ovarian cancer
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto - Oncogene, 2017 - inis.iaea.org
[en] Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in
over 30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
over 30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
[PDF][PDF] Iron addiction: a novel therapeutic target in ovarian cancer
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto… - Oncogene, 2017 - researchgate.net
Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the US,
1 and the most lethal gynecologic malignancy. 1 Ovarian cancer is a heterogeneous …
1 and the most lethal gynecologic malignancy. 1 Ovarian cancer is a heterogeneous …
Iron addiction: a novel therapeutic target in ovarian cancer.
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto… - Oncogene, 2017 - europepmc.org
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
Iron addiction: a novel therapeutic target in ovarian cancer
D Basuli, L Tesfay, Z Deng, B Paul, Y Yamamoto… - Oncogene, 2017 - osti.gov
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …
30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron …